Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome

Summary

Teva Pharmaceutical submitted a New Drug Application (NDA) to the FDA for ecopipam, a first-in-class investigational therapy for pediatric Tourette Syndrome. The submission represents a significant regulatory milestone for the company's therapeutic candidate in this indication.